CONMED Investor Presentation Q3 2024 Earnings Call Curt R. Hartman Chair of the Board, President, and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer Patrick Beyer Chief Operating Officer October 30, 2024 Forward-Looking Information 2 This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those ex ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par value CNMD NYSE FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organizati ...

Conmed (CNMD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 30. ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Conmed (CNMD) , which belongs to the Zacks Medical - Dental Supplies industry, could be a great candidate to consider. This medical technology company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 6.64%. For the last reported quarter, Conmed ...

CONMED Corporation (CNMD) is well poised for growth in the coming quarters, courtesy of its broad product spectrum. The optimism, led by the solid recurring revenue base and potential in General Surgery, is expected to contribute further. However, headwinds from supply-chain constraints and data security threats persist. Shares of this Zacks Rank #3 (Hold) company have lost 39.2% year to date compared with the industry's 1.7% fall. The S&P 500 Index has increased 20.6% in the same time frame. CONMED, a reno ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. It also includes access to the Zacks Style Scores. What are ...

Dublin, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The "Carpal Tunnel Release Systems - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Carpal Tunnel Release Systems was estimated at US$604.4 Million in 2023, and is projected to reach US$809.7 Million by 2030, growing at a CAGR of 4.3% from 2023 to 2030. The growth in the carpal tunnel release systems market is driven by several factors, including technological advancements, an increase in the prevalence ...

It has been about a month since the last earnings report for Conmed (CNMD) . Shares have added about 13.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Conmed due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. CONMED Q2 Earnings Beat, Sales Rise Y/Y,'24 View Cut ...

CONMED Corporation (CNMD) delivered adjusted earnings per share (EPS) of 98 cents in the second quarter of 2024, which beat the Zacks Consensus Estimate of 92 cents by 6.5%. The bottom line improved 18.1% from the year-ago quarter's level. GAAP EPS for the quarter was 96 cents compared with 43 cents per share in the year-ago period. The company's shares have lost 14.7% in the past six months against the industry's rise of 1.5%. The broader S&P 500 Index has gained 11.7% in the same time frame. Image Source: ...

Financial Performance - Net sales increased by 4.5% to $332.1 million for the three months ended June 30, 2024, compared to $317.7 million for the same period in 2023, primarily driven by strong growth in the general surgery product line [89]. - General surgery sales rose by 8.9% to $192.6 million for the three months ended June 30, 2024, compared to $176.9 million in the same period of 2023 [90]. - Orthopedic surgery sales decreased by 0.9% to $139.5 million for the three months ended June 30, 2024, compared to $140.8 million in the same period of 2023 [90]. - Net income increased to 9.0% for the three months ended June 30, 2024, compared to 4.3% for the same period in 2023 [88]. - Gross profit margin improved by 160 basis points to 55.3% for the three months ended June 30, 2024, compared to 53.7% for the same period in 2023 [90]. Expenses and Costs - Cost of sales increased to $148.4 million for the three months ended June 30, 2024, compared to $147.0 million for the same period in 2023 [90]. - Selling and administrative expense decreased to $122.5 million in Q2 2024 from $129.7 million in Q2 2023, representing a 5.6% decrease [92]. - Research and development expenses were 4.2% of net sales for the three months ended June 30, 2024, compared to 4.3% for the same period in 2023 [88]. - Research and development expense increased to $14.1 million in Q2 2024 from $13.6 million in Q2 2023, a 3.7% increase [94]. - Interest expense decreased to $9.6 million in Q2 2024 from $10.0 million in Q2 2023, a 4% decrease [95]. - Income tax expense recorded an effective tax rate of 20.1% for Q2 2024 compared to 21.2% for Q2 2023, reflecting a reduction of 1.1 percentage points [97]. Cash Flow and Financing - Net cash provided by operating activities was $72.4 million in the first half of 2024, significantly up from $22.8 million in the same period of 2023 [101]. - Net cash used in investing activities decreased by $4.2 million in the first half of 2024, with capital expenditures at $5.6 million compared to $8.8 million in the prior year [103]. - Net cash used in financing activities increased to $61.1 million in the first half of 2024 from $14.4 million in the same period of 2023 [104]. - The company had $114.6 million in borrowings outstanding on the term loan facility and $62.0 million on the revolving credit facility as of June 30, 2024 [106]. - The company has repurchased a total of 6.1 million shares of common stock for $162.6 million under a $200.0 million share repurchase program [108]. Market and Operational Challenges - The company expects ongoing supply chain challenges and inflationary pressures to impact results through 2024 [86]. - The company is experiencing higher manufacturing and operating costs due to inflationary pressures and ongoing supply chain challenges [106]. - International sales accounted for approximately 44% of consolidated net sales during both the six months ended June 30, 2024, and 2023 [85]. - The company derived approximately 84% of its revenues from single-use products, indicating a strong recurring revenue stream [85].